Drug Name: Aphexda

Active Ingredient: motixafortide

Indications: To use with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma

Approval Date: 9/8/2023

Company: BioLineRx USA Inc

More: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217159s000lbl.pdf

Leave a Reply

Your email address will not be published. Required fields are marked *